Oscient Factive Rash Risk In Acute Sinusitis To Be Discussed By Cmte.
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Anti-Infective Drugs Advisory Committee will consider if five-day treatment will lessen risk of gemifloxacin-associated rash at its Sept. 12 meeting.